Based on this transaction and a few others from Corporate Insiders of PRTK that Bought $1.3M worth of shares in the last 3 months, the Insider Confidence level of Paratek Pharmaceuticals is trending Up.
Since these insiders have unique insights into what's happening at Paratek Pharmaceuticals, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for PRTK:
- James Dondero - Director, Bought $1,282,056 worth of shares on 2 days ago
In addition, TradingView issued a Buy rating for PRTK over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook.
Here is a bit more on Paratek Pharmaceuticals, PRTK but please do your own research.
PRTK Summary: Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.
- Recent Last Price: $2.12
- Price Change: $0.17, 8.72%
- Yearly Gain: -34.34%
- Market Cap: $111.67M
- P/E Ratio: -1.634
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to PRTK, you should consider joining TipRanks.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.